30 closest matches · ranked by relevance
Congenital Cytomegalovirus Infection · Maternal Cytomegalovirus Infection
Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42
Infections, Cytomegalovirus · Cytomegalovirus Infections
Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants
Cytomegalovirus Infections · Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants
Infections, Cytomegalovirus
Primary: Number of CMV Seropositive Subjects With Appearance or Increase of Anti-CMV Tegument Protein IgG Antibodies in Serum. — 5; 2 Participants
CMV
Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant — 155; 78 Participants
Cytomegalovirus Infection
Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants
Cytomegalovirus Infection
Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days
Cytomegalovirus
Primary: Number of Participants With a Complete Response — 8; 50 Participants
CMV Infection · Persistent CMV Viremia
Primary: Complete Response — 20; 57 Participants
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
Cytomegalovirus Infection
Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants
Cytomegalovirus Infections
Primary: a) CMV Viral Load — 100; 97.6; 86.36; NA percentage of agreement
Acute Lung Injury · Acute Respiratory Distress Syndrome · Respiratory Failure
Primary: Serum IL-6 Level — -0.79; -0.79 pg/mL
Cytomegalovirus (CMV) Infections Among Children and Adult Liver Transplantation Patients in China
Primary: Number of Participants With Clinically Significant CMV Reactivation or CMV Disease — 62; 89; 78; 32 Participants
Cytomegalovirus Infections
Primary: Virological Response on Treatment Week 6 — 5 Participants
CMV · CMV Infection · Hematopoietic Cell Transplant
Primary: Clinically Significant CMV Viremia for Hematopoietic Cell Transplantation/HCT Participants in the Interventional Cohort Only — 5; 0; 31; 0 Participants
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Leukemia · Lymphoma
Primary: Number of Participants With Adverse Events — 1; 31; 1; 22 Participants
HIV Infections · Cytomegalovirus Infections
Primary: Change in %CD38+ Human Leukocyte Antigen-D-related (HLA-DR)+ CD8+ T Cells From Baseline to Week 8. — 1.3; -4.0 percentage of activated T cells
Cytomegalovirus Infections
Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002
CMV · Congenital Cmv · Maternal Infections Affecting Fetus or Newborn
Primary: The Prevalence of CMV Shedding in Saliva, Urine and Vaginal Secretions of CMV Seropositive Women in Pregnancy — 27; 4; 16; 20 Participants
Leukemia · Lymphoma
Primary: Number of Participants With Non-Relapse Mortality — 0 Participants
Infections, Cytomegalovirus
Primary: Concentrations of Antibodies Against Anti-Glycoprotein B (gB) Immunoglobulin G (IgG) — 5091.4; 5495.1; 2587.2 EL.U/mL
Cytomegalovirus Infections
Primary: Cellular Immune Response in Vaccine Recipients — 14 participants
Cytomegalovirus (CMV) Infections
Primary: Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection Starting at 4 Weeks Post Last Dose (V160 3-dose Regimen Group and Placebo Group)…
Transplant Complication · CMV
Primary: Clinical Significant Leukopenia — 8; 1 Participants
Cytomegalovirus (CMV)
Primary: Percentage of Participants Who Achieved Confirmed Clearance of Plasma CMV Deoxyribose Nucleic Acid (DNA) at Week 8 — 68.3 percentage of participants
Cytomegalovirus Infection
Primary: Incidence of Cytomegalovirus (CMV) Disease. — 9; 20 participants — p=0.0396
Cytomegalovirus Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 75.0; 92.9; 84.6; 100.0 Percentage of participants
Prevention of CMV Infection or Disease
Primary: Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant — 37.5; 60.6 Percentage of participants — p=<0.0001